8月3日，阿尔尼拉姆制药公司盘中上涨5.47%，报218.375美元/股，成交额1.73亿美元。此前公司因Q2营收不及预期及全年指引下调，股价在7月30日单日暴跌逾28%。
消息面上，加拿大皇家银行于7月31日发布研报称，公司股价跌幅"看起来过度"，尽管季度表现偏软，但Amvuttra增长及管线进展仍支撑上行空间，维持跑赢大盘评级，目标价下调至350美元。Stifel同期维持买入评级，目标价调至318美元。公司Q2调整后每股收益1.84美元超预期18.71%，同比增长475%，管理层重申至2030年总收入复合增速超25%的目标。多家机构集体维持正面评级，缓解了市场恐慌情绪，推动股价技术性反弹。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.